clinical trial · NCT07199569
Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells
Bavarian Nordic·phase2·active not recruiting·n = 970
Monkeypox (Mpox)JynneosMVA-BN (Quail)
brief summary
Randomized, double-blind, phase 2b trial to assess comparability in immunogenicity, safety, and reactogenicity of MVA-BN vaccine manufactured in primary chicken embryo fibroblast (CEF) cells and the CCX.E10 quail cell line in adults
started
Oct 27, 2025
primary completion
Nov 30, 2026
completion
Nov 30, 2026
last updated
Apr 8, 2026
official title
A Randomized, Double-blind, Phase 2b Comparability Trial in Adults 18 to 49 Years of Age to Assess Immunogenicity, Safety, and Reactogenicity of the MVA-BN Vaccine Manufactured in Different Production Cells
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol